<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>407</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15701713</PubmedId>
            <Abstract>VE-cadherin is an adhesion molecule localized at the adherens junctions of endothelial cells. It is crucial for the proper assembly of vascular structures during angiogenesis and maintaining vascular integrity. We have studied 3 monoclonal antibodies (mAbs) against murine VE-cadherin that inhibit angiogenesis and tumor growth. Two of these, BV13 and 10G4, also disrupted normal vessels, resulting in severe vascular leakage, whereas the third, E4G10, did not. The goal of the current report was to identify the epitope of E4G10 and distinguish it from those of the disruptive mAbs. We mapped the epitope of E4G10 to within the first 10 amino acids of mature VE-cadherin and demonstrated that conserved tryptophan residues in this sequence are required for VE-cadherin-mediated trans-adhesion. The disruptive mAbs target a different epitope within amino acids 45 to 56, which structural homology modeling suggests is not involved in trans-adhesion. From our studies, we hypothesize that E4G10 can only bind the neovasculature, where VE-cadherin has not yet engaged in trans-adhesion and its epitope is fully exposed. Thus, E4G10 can inhibit junction formation and angiogenesis but is unable to target normal vasculature because its epitope is masked. In contrast, BV13 and 10G4 bind an epitope that is accessible regardless of VE-cadherin interactions, leading to the disruption of adherens junctions. Our findings establish the immediate N-terminal region of VE-cadherin as a novel target for inhibiting angiogenesis.</Abstract>
            <ArticleYear>2005</ArticleYear>
            <ArticlePages>4337-44</ArticlePages>
            <ArticleTitle>Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>May</LastName>
                    <ForeName>Chad</ForeName>
                </Author>
                <Author>
                    <LastName>Doody</LastName>
                    <ForeName>Jacqueline F</ForeName>
                </Author>
                <Author>
                    <LastName>Abdullah</LastName>
                    <ForeName>Rashed</ForeName>
                </Author>
                <Author>
                    <LastName>Balderes</LastName>
                    <ForeName>Paul</ForeName>
                </Author>
                <Author>
                    <LastName>Xu</LastName>
                    <ForeName>Xiaohong</ForeName>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Chien Peter</ForeName>
                </Author>
                <Author>
                    <LastName>Zhu</LastName>
                    <ForeName>Zhenping</ForeName>
                </Author>
                <Author>
                    <LastName>Shapiro</LastName>
                    <ForeName>Lawrence</ForeName>
                </Author>
                <Author>
                    <LastName>Kussie</LastName>
                    <ForeName>Paul</ForeName>
                </Author>
                <Author>
                    <LastName>Hicklin</LastName>
                    <ForeName>Daniel J</ForeName>
                </Author>
                <Author>
                    <LastName>Liao</LastName>
                    <ForeName>Fang</ForeName>
                </Author>
                <Author>
                    <LastName>Bohlen</LastName>
                    <ForeName>Peter</ForeName>
                </Author>
            </Authors>
            <ArticleChemicalList>Angiogenesis Inhibitors;Antibodies, Monoclonal;Antigens, CD;Antigens, Neoplasm;Cadherins;Epitopes;cadherin 5;Tryptophan</ArticleChemicalList>
            <ArticleMeshHeadingsList>Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal(pharmacology); Antigens, CD; Antigens, Neoplasm(immunology); Cadherins(immunology); Capillary Permeability(drug effects); Cell Line; Cell Proliferation(drug effects); Endothelium, Vascular; Epitope Mapping; Epitopes; Intercellular Junctions(drug effects); Mice; Neoplasms(blood supply; drug therapy; pathology); Neovascularization, Pathologic(drug therapy; prevention &amp; control); Tryptophan</ArticleMeshHeadingsList>
            <Journal>
                <Volume>105</Volume>
                <Issue>11</Issue>
                <Title>Blood</Title>
                <Issn>1528-0020</Issn>
                <MedlineTa>Blood</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>mouse VE-cadherin aa 1-15</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>DWIWNQMHIDEEKNE</LinearSequence>
                        <StartingPosition>46</StartingPosition>
                        <EndingPosition>60</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P55284.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10090</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 2 a, c</LocationOfData>
                <EpitopeId>10815</EpitopeId>
                <ReferenceStartingPosition>1</ReferenceStartingPosition>
                <ReferenceEndingPosition>15</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>Antibody (E4G10) was elicited by immunizing with mature VE-cadherin aa 1-15 but the epitope was mapped further to aa 1-10. The epitope is recognized by an antibody (E4G10) that inhibits angiogenesis and tumor growth without disrupting normal vessels, which results in vascular leakage. The precursor protein is processed; the mature protein's N-terminus starts at aa 46.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <BCellId>5554</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000662</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>DWIWNQMHIDEEKNE</LinearSequence>
                                            <StartingPosition>46</StartingPosition>
                                            <EndingPosition>60</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P55284.2</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10090</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>mouse VE-cadherin aa 1-15</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <IedbAccession>SRC40074</IedbAccession>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>55429</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>E4G10</AssayedAntibodyName>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>sequentially truncated soluble mouse-VE-cadherin-Fc proteins</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MQRLTELATALGAFLGLLAVAAMAGPNFPQIDTPNMLPAHHRQKRDWIWNQMHIDE</LinearSequence>
                                        <StartingPosition>1</StartingPosition>
                                        <EndingPosition>56</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P55284.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1048</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000662</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>DWIWNQMHIDEEKNE</LinearSequence>
                                            <StartingPosition>46</StartingPosition>
                                            <EndingPosition>60</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P55284.2</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10090</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>mouse VE-cadherin aa 1-15</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <IedbAccession>SRC40074</IedbAccession>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>55429</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>139</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Identification of the residues of the epitope was performed via mutation (Alanine scan) and truncation analysis.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>E4G10</AssayedAntibodyName>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>mouse VE-cadherin aa 1-15</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>DWIWNQMHIDEEKNE</LinearSequence>
                                        <StartingPosition>46</StartingPosition>
                                        <EndingPosition>60</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P55284.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>mouse VE-cadherin aa 45-56</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>IFGVDANTGNVL</LinearSequence>
                        <StartingPosition>90</StartingPosition>
                        <EndingPosition>101</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P55284.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10090</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 2 a, c</LocationOfData>
                <EpitopeId>26076</EpitopeId>
                <ReferenceStartingPosition>45</ReferenceStartingPosition>
                <ReferenceEndingPosition>56</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The epitope is recognized by monoclonal antibodies (BV13 and 10G4) that inhibit angiogenesis and tumor growth. They also disrupt normal vessels resulting in severe vascular leakage. The precursor protein is processed; the mature protein's N-terminus starts at aa 46.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>7524</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10090</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P55284.2</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>10090</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>smVEC-Fc; soluble mouse VE-cadherin-Fc fusion protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>139</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Identification of the epitope was performed via substitution of mouse with human residues on a fragment of VE-cadherin (aa 1-56) and measurement of the corresponding decrease in binding; the epitope was narrowed to aa 45-56.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>10G4</AssayedAntibodyName>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MQRLTELATALGAFLGLLAVAAMAGPNFPQIDTPNMLPAHHRQKRDWIWNQMHIDE</LinearSequence>
                                        <StartingPosition>1</StartingPosition>
                                        <EndingPosition>56</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P55284.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <BCellId>7526</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000662</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>IFGVDANTGNVL</LinearSequence>
                                            <StartingPosition>90</StartingPosition>
                                            <EndingPosition>101</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P55284.2</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10090</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>soluble mouse VE-cadherin-human Fc fusion protein</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>139</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Identification of the epitope was performed via substitution of mouse with human residues on a fragment of VE-cadherin (aa 1-56) and measurement of the corresponding decrease in binding; the epitope was narrowed to aa 45-56.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>BV13</AssayedAntibodyName>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MQRLTELATALGAFLGLLAVAAMAGPNFPQIDTPNMLPAHHRQKRDWIWNQMHIDE</LinearSequence>
                                        <StartingPosition>1</StartingPosition>
                                        <EndingPosition>56</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P55284.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

